This inventor holds 6 USPTO granted patents. Top assignees: Eli Lilly and Company, University of Hawai'i. Active years: 1989-2005.
Company Filing History:
6 out of 4,507 
2 out of 267 
Years Active: 1989-2005
Title: Tim A Smitka: Innovator in Antibiotic Development
Introduction
Tim A Smitka is a notable inventor based in Indianapolis, IN (US), recognized for his contributions to the field of antibiotic development. With a total of six patents to his name, Smitka has made significant strides in creating novel compounds that address critical health challenges.
Latest Patents
Among his latest patents, Smitka has developed lipoglycopeptide antibiotics that exhibit bacterial signal peptidase inhibitory activity. These innovative lipoglycopeptides are produced by specific actinomycete strains and have applications in both human and veterinary medicine. Additionally, he has patented new hapalindole-type alkaloids, designated as A89271 A-F and I, which serve as antifungal and antitumor agents. His work includes methods for culturing blue-green algae to produce these valuable compounds, offering new avenues for treating bacterial infections and inhibiting fungal growth.
Career Highlights
Smitka has had a distinguished career, working with prominent organizations such as Eli Lilly and Company and the University of Hawai'i. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Richard E Moore and Gregory M Patterson, who have played a role in advancing his research initiatives.
Conclusion
Tim A Smitka's innovative work in antibiotic development highlights his commitment to addressing pressing health issues through scientific research. His contributions continue to impact both human and veterinary medicine positively.